



Shionogi Europe - Methodological Notes



General Principles

Shionogi operates in Europe via Shionogi Limited in UK, Shionogi GmbH in Germany, Shionogi S.r.l. in Italy and Shionogi SLU in Spain.

Transfers of value initiated by any company in the Shionogi European Group to HCPs, HCOs and ORDMs resident in UK are disclosed via the abpi disclosure database.

Transfers of value initiated by any company in the Shionogi European Group to HCPs, HCOs and ORDMs resident in Germany, Italy or Spain will be disclosed by the relevant Shionogi subsidiary via their website.

Transfers of value initiated by any company in the Shionogi European Group to HCPs, HCOs and ORDMs not resident in UK, Germany, Italy or Spain, are disclosed by the Shionogi entity which initiated the transaction.

Transfers of value initiated by Shionogi's Head Office in Osaka (Shionogi & Co. Ltd.) to HCOs, HCPs and ORDMs resident in UK, Germany, Italy or Spain, are disclosed by the Shionogi entity in the country where the HCO, HCP or ORDM resides.

Transfers of value initiated by Shionogi Limited's US affiliate, Shionogi Inc, to HCOs, HCPs and ORDMs resident in UK, Germany, Italy or Spain, are disclosed by the Shionogi entity in the country where the HCO, HCP or ORDM resides.

Transfers of value initiated by third party suppliers on behalf of Shionogi to HCOs, HCPs and ORDMs resident in UK, Germany, Italy or Spain, are disclosed in the template of the country where the HCO, HCP or ORDM resides.

Transfers of value initiated by third party suppliers on behalf of Shionogi to HCOs, HCPs and ORDMs resident in countries other than UK, Germany, Italy or Spain, are disclosed via the abpi disclosure database.

Transfers of value by CROs on behalf of Shionogi Limited to HCPs participating in clinical trials are disclosed in aggregate in the R&D total via the abpi disclosure database.

Transfers of value are disclosed on a gross basis (ie including VAT where this is applicable).

Transfers of value are reported based on the date the payment or transfer of value took place.



Methodology by source of Transfer of Value

Shionogi Limited

- Payments direct to HCPs and HCOs resident in UK in connection with clinical trials have been reported in aggregate under the R&D heading.
- Payments to HCPs or HCOs in Germany, Italy and Spain will be reported in the local jurisdiction using the appropriate template via the relevant company's website.
- All other payments to HCPs resident either in the UK or elsewhere, where we have consent to disclose, are included in the detailed disclosures.
- All other payments to HCPs resident either in the UK or elsewhere, where we have do not have consent to disclose, are included in the aggregate disclosures.

Shionogi & Co. Ltd. – Japan Head Office

- Payments by Shionogi & Co Ltd to HCOs resident in the UK in calendar year 2016 have been included in the detailed disclosures.

Shionogi Inc. – USA

- Payments by Shionogi Inc to HCPs based in the UK in connection with a clinical trial have been reported in aggregate under the R&D heading.

Payments by third parties for interviews with experts

- Payments made by a third party supplier on behalf of Shionogi to HCPs resident in the UK have been disclosed in aggregate.

Payments by third parties for clinical trial planning and execution

- Shionogi reimburses CROs for payments they make to HCPs participating in clinical trials. Payments to such HCPs resident in the UK, have been reported in aggregate under the R&D heading.
- A third party supplier made payments on behalf of Shionogi to HCPs in connection with their participation in an investigator meeting to plan for a clinical trial. These payments are disclosed in aggregate under the R&D heading.